Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

Iberdomide - Celgene Corporation

Next Previous
Drug Profile

Iberdomide - Celgene Corporation

Alternative Names: CC-220; IBER; Iberdomide hydrochloride

Latest Information Update: 20 Dec 2019

Price : $50 *
  • Adis is an information provider. We do not sell or distribute actual drugs.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase.
  • A link to download a PDF version of the drug profile will be included in your email receipt.

At a glance

  • Originator Celgene Corporation
  • Class Anti-inflammatories; Antineoplastics; Isoindoles; Piperidones; Skin disorder therapies; Small molecules
  • Mechanism of Action CRBN protein modulators; Natural killer cell stimulants; T lymphocyte stimulants; Ubiquitin protein ligase complex modulators
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No
  • New Molecular Entity Yes

Highest Development Phases

  • Phase II Systemic lupus erythematosus
  • Phase I/II Multiple myeloma
  • Discontinued Cutaneous lupus erythematosus; Haematological malignancies; Sarcoidosis; Systemic scleroderma

Most Recent Events

  • 07 Dec 2019 Efficacy and pharmacodynamics data from from a phase Ib/IIa trial in Multiple myeloma presented at the 61st Annual Meeting and Exposition of the American Society of Hematology (ASH-Hem-2019)
  • 07 Dec 2019 Pharmacodynamics data from a preclinical study in Multiple myeloma presented at the 61st Annual Meeting and Exposition of the American Society of Haematology (ASH- Hem-2019)
  • 07 Dec 2019 Pharmacodynamics data from from a phase Ia/IIa trial in Multiple myeloma presented at the 61st Annual Meeting and Exposition of the American Society of Hematology (ASH-2019)
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Legal

Back to top